CIK: 1082554
Company Name: UNITED THERAPEUTICS CORP
Form Type : 10-K
Filing Date: 2019-02-27
Accession Number: 0001047469-19-000724


Item 1 Business Item 1 In addition, we are developing new products to treat PAH (esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag and Aurora GT), as well as a product to treat IPF (SM04646). We are also heavily engaged in early stage research and development of a number of organ transplantation related technologies including regenerative medicine, xenotransplantation, biomechanical lungs and ex vivo lung perfusion. Finally, we are engaged in additional, early stage research and development efforts in PAH and other diseases. For additional detail regarding our research and development programs, see We are engaged in research and development of new formulations, indications and delivery devices for our existing products. In particular, we are developing the Implantable System for Remodulin and the RemUnity system for delivery of intravenous and subcutaneous Remodulin, respectively. We are studying Tyvaso in patients with WHO Group 3 pulmonary hypertension and Orenitram in patients with WHO Group 2 pulmonary hypertension. We are also studying dinutuximab in patients with small cell lung cancer. Research and Development Item 1 Business Our Commercial Products. For additional detail regarding our commercial products, see , a monoclonal antibody approved by the FDA and Health Canada for the treatment of high risk neuroblastoma. Unituxin Table of Contents 60 , an oral PDE 5 inhibitor approved by the FDA to improve exercise ability in PAH patients. Adcirca , a tablet dosage form of treprostinil approved by the FDA to improve exercise capacity in PAH patients. Orenitram , an inhaled formulation of treprostinil, approved by the FDA and regulatory authorities in Argentina and Israel to improve exercise ability in PAH patients. Tyvaso , a continuously infused formulation of the prostacyclin analogue treprostinil, approved by the FDA for subcutaneous and intravenous administration to diminish symptoms associated with exercise in PAH patients. Remodulin has also been approved in various countries outside of the United States. Remodulin We currently market and sell the following commercial products Overview of Marketed Products The following discussion should be read in conjunction with our consolidated financial statements and related notes to our consolidated financial statements. ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS to our consolidated financial statements for the computation of basic and diluted net income per share. Stockholders' Equity Earnings Per Common Share Refer to Note 11 (1) 1,2424 $ 1,588.6 $ 1,8513 $ 2,1018 $ 2,788.6 $ Total stockholders' equity 114.5 $ 144.0 $ 130.9 $ 3137 $ 316.6 $ Total non current liabilities 1,884.4 $ 2,184.4 $ 2,325.6 $ 2,879.4 $ 3,4010 $ Total assets 818.2 $ 9918 $ 1,0531 $ 1,430.1 $ 1,858.5 $ Cash, cash equivalents and marketable investments Consolidated Balance Sheet Data 2014 2015 2016 2017 2018 As of December 31, 6.28 $ 1272 $ 15.25 $ 9.31 $ 1339 $ (1) Diluted 7.06 $ 14.17 $ 16.29 $ 9.50 $ 1354 $ (1) Basic Net income per common share 340.1 $ 6516 $ 7137 $ 417.9 $ 589.2 $ Net income 538.8 $ 699.0 $ 1,0617 $ 814.9 $ 805.4 $ Operating income 1,288.5 $ 1,465.8 $ 1,598.8 $ 1,725.3 $ 1,627.8 $ Revenues Consolidated Statements of Operations Data 2014 2015 2016 2017 2018 Year Ended December 31, included in this Report. The historical results are not necessarily indicative of results to be expected for future periods. The following information is presented in millions, except per share data. Item 7 Management's Discussion and Analysis of Financial Condition and Results of Operations The following selected consolidated financial data should be read in conjunction with our consolidated financial statements and the notes accompanying the consolidated financial statements and ITEM 6. SELECTED FINANCIAL DATA Table of Contents 59 The following chart shows the performance from December 31, 2013 through December 31, 2018 of our common stock, compared with an investment in the stocks represented in each of the Nasdaq U.S. Benchmark TR Index and the Nasdaq ICB 4577 Pharmaceutical Stock Index, assuming the investment of $100 at the beginning of the period and the reinvestment of dividends, if any. Comparison of Five Year Total Cumulative Shareholder Return We did not repurchase any of our outstanding equity securities during the 3 months ended December 31, 2018, as our most recent share repurchase program was completed in September 2017. Issuer Purchases of Equity Securities We have never paid and have no present intention to pay cash dividends on our common stock in the foreseeable future and our 2018 Credit Agreement contains covenants that may restrict us from doing so. We intend to retain any earnings for use in our business operations. Dividend Policy As of February 20, 2019, there were 36 holders of record of our common stock. Number of Holders Our common stock trades on the Nasdaq Global Select Market under the symbol "UTHR". Market Information ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES I Table of Contents 58 Not applicable. ITEM 4. MINE SAFETY DISCLOSURES , to our consolidated financial statements, which is incorporated herein by reference. Litigation Currently, and from time to time, we are subject to claims in legal proceedings arising in the normal course of business. While we presently believe that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, cash flows or results of operations, legal proceedings are inherently uncertain, and unfavorable rulings could, individually or in aggregate, have a material adverse effect on our business, financial condition or operating results. Please refer to Note 17 ITEM 3 LEGAL PROCEEDINGS We believe that these facilities, along with various other owned and leased facilities, are adequate for our current operations and that additional land and facilities for future expansion are reasonably available. Florida We own 2 buildings in Brevard County, Florida used for strategic operations and planning. We are also constructing a 75,000 square foot building in Jacksonville, Florida, to serve as a regional ex vivo lung perfusion facility as part of our collaboration with the Mayo Clinic. District of Columbia We own four adjacent buildings in Washington, D.C. totaling 30,000 square feet, which serve as office space. North Carolina We own a 380,000 square foot combination manufacturing facility and office building in Research Triangle Park, North Carolina (RTP facility), which serves as our co headquarters and is occupied by our clinical research and development, commercialization and our logistics and manufacturing personnel. We manufacture Orenitram tablets and we package, warehouse and distribute Remodulin, Tyvaso, Orenitram and Unituxin at this location. We also own a 132 acre site containing approximately 330,000 square feet of building space adjacent to our RTP facility, which we use for our research, development and manufacturing facilities related to our lung regeneration program, office space and for future expansion. Maryland We own and occupy a 353,000 square foot combination laboratory and office building complex in Silver Spring, Maryland that serves as our co headquarters and is used for commercial manufacturing. These manufacturing activities include the synthesis of treprostinil, the active ingredient in Remodulin and Tyvaso, and treprostinil diolamine, the active ingredient in Orenitram, as well as dinutuximab, the active ingredient in Unituxin. We also manufacture finished Remodulin, Tyvaso and Unituxin in our Silver Spring complex. We own several other buildings in Silver Spring used principally for office and laboratory space. We are constructing a 29,000 square foot facility in Silver Spring to serve as a monoclonal antibody manufacturing site. ITEM 2 PROPERTIES 
